

**BETAMETHASONE DIPROPIONATE - betamethasone dipropionate cream**  
**H.J. Harkins Company, Inc.**

-----  
**Betamethasone Dipropionate Cream, 0.05% (Augmented\*)**  
**(potency expressed as betamethasone)**


\*Vehicle augments the penetration of the steroid.

**For Dermatologic Use Only - Not for Ophthalmic Use**

**DESCRIPTION**

Betamethasone dipropionate cream, 0.05% (augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.

Chemically, betamethasone dipropionate is 9-fluoro-11 $\beta$ ,17,21-trihydroxy-16 $\beta$ -methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C<sub>28</sub>H<sub>37</sub>FO<sub>7</sub>, a molecular weight of 504.6, and the following structural formula :



Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water.

Each gram of betamethasone dipropionate cream, 0.05% (augmented) contains: 0.643 mg betamethasone dipropionate USP (equivalent to 0.5 mg betamethasone) in an emollient cream base of purified water USP; chlorocresol NF; propylene glycol USP; white petrolatum USP; white wax NF; cyclomethicone NF; sorbitol solution USP; glyceryl oleate/propylene glycol; cetareth-30; carbomer homopolymer NF; and sodium hydroxide NF.

**CLINICAL PHARMACOLOGY**

The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.

Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.

### **Pharmacokinetics:**

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. (See **DOSAGE AND ADMINISTRATION** section.)

Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. (See **DOSAGE AND ADMINISTRATION** section.)

Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Betamethasone dipropionate cream, 0.05% (augmented) was applied once daily at 7 grams per day for 1 week to diseased skin, in adult patients with psoriasis or atopic dermatitis, to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis. The results suggested that the drug caused a slight lowering of adrenal corticosteroid secretion, although in no case did plasma cortisol levels go below the lower limit of the normal range.

Sixty-seven pediatric patients ages 1 to 12 years, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Betamethasone dipropionate cream, 0.05% (augmented) was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). In 19 of 60 (32%) evaluable patients, adrenal suppression was indicated by either a  $\leq 5$  mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol  $\leq 8$  mcg/dL and/or an increase of  $< 7$  mcg/dL from the baseline cortisol. Studies performed with betamethasone dipropionate cream, 0.05% (augmented) indicate that it is in the high range of potency as compared with other topical corticosteroids.

### **INDICATIONS AND USAGE**

Betamethasone dipropionate cream, 0.05% (augmented) is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.

### **CONTRAINDICATIONS**

Betamethasone dipropionate cream, 0.05% (augmented) is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

### **PRECAUTIONS**

#### **General**

Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. (See **DOSAGE AND ADMINISTRATION** section.)

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 60 evaluable patients, of the 19 who showed evidence of suppression 4 patients were tested 2 weeks after discontinuation of betamethasone dipropionate cream, 0.05% (augmented) and 3 of the 4 (75%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See **PRECAUTIONS: Pediatric Use.**)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

### **Information For Patients:**

Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

1. This medication is to be used as directed by the physician and should not be used longer than the prescribed time period. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive. (See **DOSAGE AND ADMINISTRATION** section.)
4. Patients should report any signs of local adverse reactions.
5. Other corticosteroid-containing products should not be used with betamethasone dipropionate cream, 0.05% (augmented) without first talking to your physician.

### **Laboratory Tests:**

The following tests may be helpful in evaluating HPA axis suppression:

Urinary free cortisol test  
ACTH stimulation test

### **Carcinogenesis, Mutagenesis, and Impairment of Fertility:**

Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.

Betamethasone was negative in the bacterial mutagenicity assay (*Salmonella typhimurium* and *Escherichia coli*), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the *in-vitro* human lymphocyte chromosome aberration assay, and equivocal in the *in-vivo* mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone.

Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1.0 mg/kg by the intramuscular route and in mice up to 33 mg/kg by the intramuscular route indicated no impairment of

fertility except for dose-related increases in fetal resorption rates in both species. These doses are approximately 5- and 38-fold the human dose based on a mg/m<sup>2</sup> comparison, respectively.

### **Pregnancy:**

Teratogenic Effects: Pregnancy Category C:

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.

Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2-fold the maximum human dose based on a mg/m<sup>2</sup> comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.

Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

### **Nursing Mothers:**

It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

### **Pediatric Use:**

Use of betamethasone dipropionate cream, 0.05% (augmented) in pediatric patients 12 years of age and younger is not recommended. (See **CLINICAL PHARMACOLOGY** and **ADVERSE REACTIONS** sections.) In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged 3 months-12 years old) using betamethasone dipropionate cream, 0.05% (augmented) for treatment of atopic dermatitis demonstrated HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group. (See **CLINICAL PHARMACOLOGY: Pharmacokinetics**.)

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. The study described above supports this premise, as adrenal suppression in 9-12 year olds, 6-8 year olds, 2-5 year olds, and 3 months-1 year old was 17%, 32%, 38% and 50% respectively.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.

### **Geriatric Use:**

Clinical studies of betamethasone dipropionate cream, 0.05% (augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.

## ADVERSE REACTIONS

The only local adverse reaction reported to be possibly or probably related to treatment with betamethasone dipropionate cream, 0.05% (augmented) during adult controlled clinical studies was stinging. It occurred in 1 patient, 0.4%, of the 242 patients or subjects involved in the studies.

Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate cream, 0.05% (augmented) during a pediatric clinical study include signs of skin atrophy (telangiectasia, bruising, shininess). Skin atrophy occurred in 7 of 67 (10%) patients, involving all age groups from 3 months - 12 years of age.

The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

## OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See **PRECAUTIONS.**)

## DOSAGE AND ADMINISTRATION

Apply a thin film of betamethasone dipropionate cream, 0.05% (augmented) to the affected skin areas once or twice daily. Treatment with betamethasone dipropionate cream, 0.05% (augmented) should be limited to 45 g per week.

**Betamethasone dipropionate cream, 0.05% (augmented) is not to be used with occlusive dressings.**

## HOW SUPPLIED

Betamethasone dipropionate cream, 0.05% (augmented) is supplied in 15 g (NDC 68462-290-17) and 50 g (NDC 68462-290-52); boxes of one.

**Store at 25°C (77°F); excursions permitted to 15 - 30°C (59 - 86°F) [see USP Controlled Room Temperature].**

Manufactured:

**Glenmark Generics Ltd.**

Village: Kishanpura, Baddi Nalagarh Road

District: Solan, Himachal Pradesh - 174101, India

Manufactured for:



**Glenmark Generics Inc., USA**

Mahwah, NJ 07430

Questions? 1 (888)721-7115

[www.glenmarkgenerics.com](http://www.glenmarkgenerics.com)

February 2011

Repacked by:  
H.J. Harkins Company, Inc.  
513 Sandydale Drive  
Nipomo, CA 93444

**52959-124-50** RX Only: #XXXXXXXXX #XXX

**BETAMETH. DIPROP. 0.05% AF CRM**

Lot #: BTD00KG  
Mfg: GLENMARK  
Exp: 01/13 Compare to: Diprolene AF  
Mfg India Mfg. NDC: 68462-290-52  
Loc.: Pill ID:

CAUTION: Federal law PROHIBITS the transfer of this drug to anyone other than the person to whom prescribed and prohibits dispensing without a prescription unless OTC. See outsert for add'l RX info KEEP OUT OF REACH OF CHILDREN. Store in a cool dry place 68 to 77 degrees F.

BETAMETH. DIPROP. 0.05% AF CRM  
52959-124-50 Qty 50gm  
01/13 Lot BTD00KG  
Diprolene AF 68462-290-52

BETAMETH. DIPROP. 0.05% AF CRM  
52959-124-50 Qty 50gm  
01/13 Lot BTD00KG  
Diprolene AF 68462-290-52

BETAMETH. DIPROP. 0.05% AF CRM  
52959-124-50 Qty 50gm  
01/13 Lot BTD00KG  
Diprolene AF 68462-290-52

BETAMETH. DIPROP. 0.05% AF CRM  
52959-124-50 Qty 50gm  
01/13 Lot BTD00KG  
Diprolene AF 68462-290-52

Take as directed by your Doctor or  
See outsert for usual dosage information

Repack: HJ Harkins Co., Inc. Nipomo., CA 93444  
Dispense in tight, child & light-resistant container per USP

## BETAMETHASONE DIPROPIONATE

betamethasone dipropionate cream

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:52959-124(NDC:68462-290)
Route of Administration	TOPICAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)	BETAMETHASONE	0.5 mg in 1 g

### Inactive Ingredients

Ingredient Name	Strength
CHLOROCRESOL (UNII: 36W53O7109)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
SORBITOL (UNII: 506T60A25R)	
PETROLATUM (UNII: 4T6H12BN9U)	
WHITE WAX (UNII: 7G1J5DA97F)	
CARBOMER HOMOPOLYMER TYPE C (UNII: 4Q93RCW27E)	

CYCLOMETHICONE (UNII: NMQ347994Z)

CETEARETH-30 (UNII: 1R9DCZ5FOX)

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:52959-124-50	50 g in 1 TUBE		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA078930	09/23/2008	

**Labeler** - H.J. Harkins Company, Inc. (147681894)

**Registrant** - Glenmark Generics Inc., USA (835917282)

### Establishment

Name	Address	ID/FEI	Business Operations
Glenmark Pharmaceuticals Limited		676 115028	ANALYSIS, MANUFACTURE

Revised: 1/2012

H.J. Harkins Company, Inc.